Weller, Michael ; Tabatabai, Ghazaleh ; Kästner, Bärbel ; Felsberg, Jörg ; Steinbach, Joachim P. ; Wick, Antje ; Schnell, Oliver ; Hau, Peter ; Herrlinger, Ulrich ; Sabel, Michael C. ; Wirsching, Hans-Georg ; Ketter, Ralf ; Bähr, Oliver ; Platten, Michael 
; Tonn, Jörg C. ; Schlegel, Uwe ; Marosi, Christine ; Goldbrunner, Roland ; Stupp, Roger ; Homicsko, Krisztian ; Pichler, Josef ; Nikkhah, Guido ; Meixensberger, Jürgen ; Vajkoczy, Peter ; Kollias, Spyros ; Hüsing, Johannes ; Reifenberger, Guido ; Wick, Wolfgang
; Tonn, Jörg C. ; Schlegel, Uwe ; Marosi, Christine ; Goldbrunner, Roland ; Stupp, Roger ; Homicsko, Krisztian ; Pichler, Josef ; Nikkhah, Guido ; Meixensberger, Jürgen ; Vajkoczy, Peter ; Kollias, Spyros ; Hüsing, Johannes ; Reifenberger, Guido ; Wick, Wolfgang 
Abstract
Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT -> TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen. Experimental Design: Patients with glioblastoma at ...
Owner only: item control page
Altmetric